Human Peripheral Blood Immature Dendritic Cells, Frozen

Primary human cells, frozen
Human Peripheral Blood Immature Dendritic Cells, Frozen

Primary human cells, frozen

1.5 x 10^6 cells
  • Please select one of the preferences above when ordering multiple quantities

    Please indicate any specifications (e.g. sex, age range, BMI range, ethnicity, blood type, smoker status, CMV, HLA, etc.) in the comment box below. An additional surcharge will apply to requests for CMV, HLA, or other specifications requiring new donor recruitment. Please note that highly specific or multiple specifications may affect the delivery time.

Catalog # 70041
709 USD

Overview

Primary human immature dendritic cells (DCs) were derived from immunomagnetically selected peripheral blood (PB) monocytes. Monocytes were cultured in RPMI 1640 Medium with 10% fetal bovine serum (FBS), GM-CSF and IL-4 to generate immature DCs. PB was collected using acid-citrate-dextrose solution A (ACDA) as the anticoagulant.

Cells were obtained using Institutional Review Board (IRB)-approved consent forms and protocols.

Certain products are only available in select territories. Please contact your local Sales representative or Product & Scientific Support at techsupport@stemcell.com for further information.

Browse our Frequently Asked Questions (FAQs) on Primary Cells.
Contains
• CryoStor® CS10
Subtype
Frozen
Cell Type
Dendritic Cells, Monocytes
Species
Human
Cell and Tissue Source
Peripheral Blood
Donor Status
Normal
Purity
The purity of immature DCs is ≥ 90% for CD11c and MHC class II, ≤ 30% for CD83, and ≤ 5% for CD14high by flow cytometry.

Related Products

Scientific Resources

Product Documentation

Document Type Product Name Catalog # Lot # Language
Document Type
Product Information Sheet
Product Name
Human Peripheral Blood Immature Dendritic Cells, Frozen
Catalog #
70041
Lot #
All
Language
English

Educational Materials(3)

Brochure
Human Primary Cells
Brochure
Tools For Your Immunology Research
Video
6:05
How to Thaw Frozen Human Primary Cells

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications

Publications (1)

Toxicology letters 2015 AUG Differential cytotoxicity of long-chain bases for human oral gingival epithelial keratinocytes, oral fibroblasts, and dendritic cells. Poulsen C et al.

Abstract

Long-chain bases are present in the oral cavity. Previously we determined that sphingosine, dihydrosphingosine, and phytosphingosine have potent antimicrobial activity against oral pathogens. Here, we determined the cytotoxicities of long-chain bases for oral cells, an important step in considering their potential as antimicrobial agents for oral infections. This information would clearly help in establishing prophylactic or therapeutic doses. To assess this, human oral gingival epithelial (GE) keratinocytes, oral gingival fibroblasts (GF), and dendritic cells (DC) were exposed to 10.0-640.0 μM long-chain bases and glycerol monolaurate (GML). The effects of long-chain bases on cell metabolism (conversion of resazurin to resorufin), membrane permeability (uptake of propidium iodide or SYTOX-Green), release of cellular contents (LDH), and cell morphology (confocal microscopy) were all determined. GE keratinocytes were more resistant to long-chain bases as compared to GF and DC, which were more susceptible. For DC, 0.2-10.0 μM long-chain bases and GML were not cytotoxic; 40.0-80.0 μM long-chain bases, but not GML, were cytotoxic; and 80.0 μM long-chain bases induced cellular damage and death in less than 20 min. The LD50 of long-chain bases for GE keratinocytes, GF, and DC were considerably higher than their minimal inhibitory concentrations for oral pathogens, a finding important to pursuing their future potential in treating periodontal and oral infections.
View All Publications

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.